EUVIMEDEUVIMED entdecken
Crossref

Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data

Hao Wang, Xiaoqian Xu, Lichen Shi, Cheng Huang, Yameng Sun, Hong You, Jidong Jia, You-Wen He, Yuanyuan Kong iD

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.16233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Hao Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Digestive Disease, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, …. Hauptthemen laut MEDLINE: Growth Differentiation Factor 15, Fatty Liver, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Research Grant of Capital Medical University, National Key Research and Development Program of China, Beijing Municipal Administration of Hospitals Incubating Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This study aims to determine the predictive capability for metabolic dysfunction‐associated steatohepatitis (MASH) long before its diagnosis by using six previously identified diagnostic biomarkers for metabolic dysfunction‐associated steatotic liver disease (MASLD) with proteomic data from the UK Biobank. Materials and Methods A nested case–control study comprising a MASH group and three age‐ and sex‐matched control groups (metabolic dysfunction‐associated steatosis, viral hepatitis and normal liver controls) was conducted. Olink proteomics, anthropometric and biochemical data at baseline levels were obtained from the UK Biobank. The baseline levels of CDCP1, FABP4, FGF21, GDF15, IL‐6 and THBS2 were analysed prospectively to determine their predictive accuracy for subsequent diagnosis with a mean lag time of over 10 years.

Results

At baseline, GDF15 demonstrated the best performance for predicting MASH occurrence at 5 and 10 years later, with AUCs of 0.90 at 5 years and 0.86 at 10 years. A predictive model based on four biomarkers (GDF15, FGF21, IL‐6 and THBS2) showed AUCs of 0.88 at both 5 and 10 years. Furthermore, a protein‐clinical model that included these four circulating protein biomarkers along with three clinical factors (BMI, ALT and TC) yielded AUCs of 0.92 at 5 years and 0.89 at 10 years.

Conclusions

GDF15 at baseline levels outperformed other individual circulating protein biomarkers for the early prediction of MASH. Our data suggest that GDF15 and the GDF15‐based model may be used as easy‐to‐implement tools to identify patients with high risks of developing MASH at a mean lag time of over 10 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation Factor 15Fatty LiverNon-alcoholic Fatty Liver DiseaseHumansCase-Control StudiesFemaleMaleBiomarkersMiddle AgedUnited KingdomProteomicsAdultBiological Specimen BanksAgedFibroblast Growth FactorsPredictive Value of TestsUK Biobank

Stichwörter der Autor:innen

growth differentiation factor 15metabolic dysfunction‐associated steatohepatitismetabolic dysfunction‐associated steatotic liver diseasepredictive biomarkersproteomics

Substanzen

Growth Differentiation Factor 15BiomarkersGDF15 protein, humanFibroblast Growth FactorsFGF21 protein, human

Autor:innen und Institutionen

  • National Clinical Research Center for Digestive Disease, State Key Lab of Digestive Health, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
  • Department of Clinical Epidemiology and Evidence-Based Medicine, Beijing Clinical Research Institute, Beijing, China.
  • Department of Integrative Immunobiology, Duke University School of Medicine, Durham, North Carolina, USA.

ORCID-Profile: Yuanyuan Kong

Förderung

  • Research Grant of Capital Medical University
  • National Key Research and Development Program of China
  • Beijing Municipal Administration of Hospitals Incubating Program
  • High-level Public Health Technical Talents of the Beijing Municipal Health Commission

Zitieren

APA

Wang, H., Xu, X., Shi, L., Huang, C., Sun, Y., You, H., Jia, J., He, Y. W., & Kong, Y. (2025). Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16233

Vancouver

Wang H, Xu X, Shi L, Huang C, Sun Y, You H, et al. Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16233

BibTeX
@article{Wang2025,
  author = {Wang, Hao and Xu, Xiaoqian and Shi, Lichen and Huang, Cheng and Sun, Yameng and You, Hong and Jia, Jidong and He, You-Wen and Kong, Yuanyuan},
  title = {Identification of growth differentiation factor 15 as an early predictive biomarker for metabolic dysfunction‐associated steatohepatitis: A nested case–control study of UK Biobank proteomic data},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.16233}
}
Kostenlos starten →